ExpreS2ion Biotech Holding AB banner
E

ExpreS2ion Biotech Holding AB
STO:EXPRS2

Watchlist Manager
ExpreS2ion Biotech Holding AB
STO:EXPRS2
Watchlist
Price: 14.78 SEK -10.96%
Market Cap: kr52.2m

ExpreS2ion Biotech Holding AB
Other Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ExpreS2ion Biotech Holding AB
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
E
ExpreS2ion Biotech Holding AB
STO:EXPRS2
Other Items
kr44k
CAGR 3-Years
-77%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Other Items
kr16k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Other Items
-kr894k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Other Items
-kr32m
CAGR 3-Years
18%
CAGR 5-Years
-200%
CAGR 10-Years
-14%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Other Items
-kr146m
CAGR 3-Years
N/A
CAGR 5-Years
55%
CAGR 10-Years
-73%
BioArctic AB
STO:BIOA B
Other Items
kr232.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ExpreS2ion Biotech Holding AB
Glance View

Market Cap
52.2m SEK
Industry
Biotechnology

Expres2ion Biotech Holding AB engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer. The company is headquartered in Helsingborg, Skane and currently employs 29 full-time employees. The company went IPO on 2016-07-29. The firm specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The firm's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. The company also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.

EXPRS2 Intrinsic Value
Not Available
E

See Also

What is ExpreS2ion Biotech Holding AB's Other Items?
Other Items
44k SEK

Based on the financial report for Sep 30, 2025, ExpreS2ion Biotech Holding AB's Other Items amounts to 44k SEK.

What is ExpreS2ion Biotech Holding AB's Other Items growth rate?
Other Items CAGR 3Y
-77%

Over the last year, the Other Items growth was -100%. The average annual Other Items growth rates for ExpreS2ion Biotech Holding AB have been -77% over the past three years .

Back to Top